National Cancer Institute Seeks Pharmaceutical Company to Develop HIF-1 Inhibitors

Summary

The National Cancer Institute is seeking a pharmaceutical or biotechnology company to develop novel small molecule inhibitors of the HIF-1 transcriptional activation pathway under a Cooperative Research and Development Agreement (CRADA) with an expected duration of one to five years.